ArticlePharmacoEconomics - open2020

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis.

Justin Carrico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.